Negative nasopharyngeal SARS-CoV-2 PCR conversion in response to different therapeutic interventions

{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2022, 9, 15]], 'date-time': '2022-09-15T10:52:14Z', 'timestamp': 1663239134875}, 'posted': {'date-parts': [[2020, 5, 11]]}, 'group-title': 'Respiratory Medicine', 'reference-count': 23, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 5, 11]]}, 'abstract': '<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>BACKGROUND</jats:title><jats:p>Despite ' 'lack of convincing evidence of the efficacy of hydroxychloroquine, it has been suggested to ' 'be used for the treatment of SARS-CoV-2 to accelerate the negative virus conversion. We aimed ' 'to explore the association between negative nasopharyngeal SARS-CoV-2 PCR clearance and ' 'different therapeutic ' 'interventions.</jats:p></jats:sec><jats:sec><jats:title>METHODOLOGY</jats:title><jats:p>This ' 'was a retrospective cohort study of 93 patients who were admitted to medical ward with a PCR ' 'confirmed diagnosis of COVID-19 and met the inclusion criteria in a tertiary hospital in ' 'Mecca, Saudi Arabia. There were three interventional subgroups (group A (n=45): who received ' 'antimalarial drug only classified as (A1), combined with azithromycin (A2) or combined with ' 'antiviral drugs (A3)), and one supportive care group (group B) (n=48). The primary and ' 'secondary endpoints of the study were achieving negative SARS-CoV-2 nasopharyngeal PCR sample ' 'within five days or less from the start of the intervention and 12 days or less from the ' 'diagnose, ' 'respectively.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>The mean ' 'age of the patients was 43.9 years (SD:15.9). A median time of 3.00 days (IQR:2.00-6.50) ' 'needed from the time of starting the intervention/supportive care to the first negative PCR ' 'sample. There was no statistically significant difference neither between the percentage of ' 'patients in the interventional group and the supportive care group who achieved the primary ' 'or the secondary endpoint, nor in the median time needed to achieve the first negative PCR ' 'sample ' '(p&gt;0.05).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p>Prescribing ' 'antimalarial medications was not shown to shorten the disease course nor to accelerate the ' 'negative PCR conversion rate.</jats:p></jats:sec>', 'DOI': '10.1101/2020.05.08.20095679', 'type': 'posted-content', 'created': {'date-parts': [[2020, 5, 11]], 'date-time': '2020-05-11T22:25:15Z', 'timestamp': 1589235915000}, 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic ' 'interventions', 'prefix': '10.1101', 'author': [ {'given': 'Mohammed Hassan', 'family': 'Shabrawishi', 'sequence': 'first', 'affiliation': []}, {'given': 'Abdallah Y', 'family': 'Naser', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hassan', 'family': 'Alwafi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ahmad Mansoor', 'family': 'Aldobyany', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Abdelfattah Ahmed', 'family': 'Touman', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021011111121549000_2020.05.08.20095679v1.1', 'unstructured': 'World Health Organization. Coronavirus disease 2019 (COVID-19): ' 'situation report—70 2020 [Available from: ' 'https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200330-sitrep-70-covid-19.pdf?sfvrsn=7e0fe3f82.'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/s01406736(20)30211-7'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.3', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2001468'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.2565'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.5', 'unstructured': 'Chinese national health commission and stat administration of ' 'traditional Chinese medicine. Diagnosis and treatment protocol for novel ' 'corona viruses pneumonia. 2020.'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.6', 'unstructured': 'Saudi center for disease prevention and control. Quick interim guide to ' 'COVID-19 surveillance case definition and disposition. 2020.'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.7', 'unstructured': 'Centre for Disease Control and Prevention. Information for Clinicians on ' 'Investigational Therapeutics for Patients with COVID-19 2020 [updated ' 'April 25, 2020. Available from: ' 'https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html.'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.8', 'doi-asserted-by': 'crossref', 'unstructured': 'Colson P , Rolain J , Raoult D . Chloroquine for the 2019 novel ' 'coronavirus SARSCoV-2. Int J Antimicrob Agents. 2020.', 'DOI': '10.1016/j.ijantimicag.2020.105923'}, { 'issue': '4', 'key': '2021011111121549000_2020.05.08.20095679v1.9', 'doi-asserted-by': 'crossref', 'first-page': '105932', 'DOI': '10.1016/j.ijantimicag.2020.105932', 'article-title': 'Chloroquine and hydroxychloroquine as available weapons to fight ' 'COVID-19', 'volume': '55', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.10', 'doi-asserted-by': 'crossref', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is ' 'effective in inhibiting SARS-CoV-2 infection in vitro', 'volume': '6', 'year': '2020', 'journal-title': 'Cell Discov'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.11', 'doi-asserted-by': 'crossref', 'unstructured': 'Yao X , Ye F , Zhang M , Cui C , Huang B , Niu P , et al. In Vitro ' 'Antiviral Activity and Projection of Optimized Dosing Design of ' 'Hydroxychloroquine for the Treatment of Severe Acute Respiratory ' 'Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020.', 'DOI': '10.1093/cid/ciaa237'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.12', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41422-020-0282-0'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.13', 'doi-asserted-by': 'crossref', 'unstructured': 'Gautret P , Lagier JC , Parola P , Hoang VT , Meddeb L , Mailhe M , et ' 'al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: ' 'results of an open-label nonrandomized clinical trial. Int J Antimicrob ' 'Agents. 2020: 105949.', 'DOI': '10.1016/j.ijantimicag.2020.105949'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.14', 'unstructured': 'Chen J , Liu D , Liu L , Liu P , Xu Q , Xia L . A pilot study of ' 'hydroxychloroquine in treatment of patients with common coronavirus ' 'disease-19 (COVID-19). J of Zjeijang University. 2020;49(1).'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.15', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m1432'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.16', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/0310057X0903700112'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.17', 'doi-asserted-by': 'crossref', 'unstructured': 'Chorin E , Dai M , Shulman E , Wadhwani L , Bar Cohen R , Barbhaiya C , ' 'et al. The QT interval in patients with SARS-CoV-2 infection treated ' 'with hydroxychloroquine/azithromycin. [[Preprint]]. In press 2020.', 'DOI': '10.1101/2020.04.02.20047050'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.18', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/gut.35.4.569'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.19', 'doi-asserted-by': 'publisher', 'DOI': '10.1046/j.1365-2230.2001.00857-3.x'}, { 'issue': '10229', 'key': '2021011111121549000_2020.05.08.20095679v1.20', 'doi-asserted-by': 'crossref', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'article-title': 'Clinical course and risk factors for mortality of adult inpatients with ' 'COVID-19 in Wuhan, China: a retrospective cohort study', 'volume': '395', 'year': '2020', 'journal-title': 'The Lancet'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.21', 'doi-asserted-by': 'crossref', 'unstructured': 'Gautret P , Lagier JC , Parola P , Hoang VT , Meddeb L , Sevestre J , et ' 'al. Clinical and microbiological effect of a combination of ' 'hydroxychloroquine and azithromycin in 80 COVID-19 patients with at ' 'least a six-day follow up: A pilot observational study. Travel Med ' 'Infect Dis. 2020: 101663.', 'DOI': '10.1016/j.tmaid.2020.101663'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.22', 'unstructured': 'Saudi Ministry of Health. Protocol for Adults Patients Suspected ' 'of/Confirmed with COVID-19 Supportive care and antiviral treatment of ' 'suspected or confirmed COVID-19 infection. 2020.'}, { 'key': '2021011111121549000_2020.05.08.20095679v1.23', 'doi-asserted-by': 'crossref', 'unstructured': 'Magagnoli J , Narendran S , Pereira F , Cummings T , Hardin JW , Sutton ' 'SS , et al. Outcomes of hydroxychloroquine usage in United States ' 'veterans hospitalized with Covid-19 [Preprint]. In press 2020.', 'DOI': '10.1101/2020.04.16.20065920'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.05.08.20095679', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 1, 14]], 'date-time': '2021-01-14T05:45:13Z', 'timestamp': 1610603113000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2020.05.08.20095679'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 5, 11]]}, 'references-count': 23, 'URL': 'http://dx.doi.org/10.1101/2020.05.08.20095679', 'relation': {}, 'published': {'date-parts': [[2020, 5, 11]]}, 'subtype': 'preprint'}